The 7 major gerstmann-straussler-scheinker disease markets reached a value of USD 14.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 30.1 Million by 2035, exhibiting a growth rate (CAGR) of 7.30% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 14.1 Million |
Market Forecast in 2035
|
USD 30.1 Million |
Market Growth Rate 2025-2035
|
7.30% |
The gerstmann-straussler-scheinker disease market has been comprehensively analyzed in IMARC's new report titled "Gerstmann-Straussler-Scheinker Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". GSS is a rare, autosomal dominant prion disease that involves the central nervous system and results in progressive neurodegeneration. It arises as a result of mutations in the PRNP gene coding for the prion protein (PrP). GSS presents in adult life with onset between age 35 and 55 and progresses slowly but inexorably to death. The illness is followed by progressive ataxia, dysarthria, spasticity, dementia, and other neurological deficits, eventually resulting in profound cognitive and motor impairment. Diagnosis of GSS disease is challenging owing to its multifaceted clinical picture. It may consist of a combination of genetic analysis, cerebrospinal fluid examination, electroencephalogram (EEG), MRI scans, and brain biopsy in certain situations. Genetic sequencing of the PRNP gene is very important in making the diagnosis, particularly in those with a family history of prion diseases.
Gerstmann-Straussler-Scheinker (GSS) disease market is being driven by mounting awareness and progress in prion disease research, resulting in enhanced diagnostic abilities and early detection methodologies. Greater access to genetic testing enables identification of risk patients, which aids in early intervention and management of disease. More funding for neurodegenerative disease research, specifically misfolded protein diseases, has helped in accelerating the creation of new drugs against prion protein aggregation and neurodegeneration. Also, increasing clinical trials of antisense oligonucleotides (ASOs), monoclonal antibodies, and gene therapies are leading to high growth opportunities for disease-modifying treatments. The use of symptomatic treatments, including memantine, acetylcholinesterase inhibitors, and anti-inflammatory medications, is designed to counteract cognitive and motor impairments, further growing the market. Further, progress in biomarker research and neuroimaging modalities, e.g., CSF analysis and PET scans, is enhancing disease monitoring and tracking of progression. Increasing regulatory interest in orphan diseases by the regulatory agencies has also spurred on fast-track designations and funding incentives, fueling innovation. All these, together, are leading to an active and dynamic GSS disease treatment landscape with possible breakthroughs in the years to come.
IMARC Group's new report provides an exhaustive analysis of the gerstmann-straussler-scheinker disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for gerstmann-straussler-scheinker disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gerstmann-straussler-scheinker disease market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current gerstmann-straussler-scheinker disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Gerstmann-Straussler-Scheinker Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies